- Lexaria Bioscience is a drug delivery technology innovator whose flagship technology, DehydraTECH(TM), provides a means of enhancing substances’ delivery time to increase their effectiveness without adverse effects
- A new podcast by NetworkNewsAudio highlights DehydraTECH’s successes in trials that measure blood pressure reduction using DehydraTECH-enhanced CBD in comparison with generic controls
- The DehydraTECH technology is also being analyzed for effectiveness in combatting inflammatory conditions, viral illnesses and alternatives to the lung-harming effects of smoking
- The company’s most recent filing with the SEC notes that its revenues more than doubled between May 2020 and May 2021, driven largely by product sales and licensing agreements
A new podcast highlights the effectiveness enhancement efforts by technology innovator Lexaria Bioscience (NASDAQ: LEXX) for treating high blood pressure (hypertension), a key risk factor for both heart disease and stroke that is common in the world’s adult populations, including in the United States.
The podcast (https://ibn.fm/LIgxT) reviews many important entrepreneurial tips to business owners from Lexaria CEO Chris Bunka. It also notes that nearly half of all Americans have high blood pressure but only about 24 percent of those afflicted with it — many of whom are younger than 40. One of the most insidious aspects of high blood pressure is that, like diabetes, the damage they can cause is often already done by the time they are diagnosed, a reason India’s government recently announced that the health department has begun screening government employees for the conditions in all departments, for example (https://ibn.fm/vvFYi).
Lexaria’s patented DehydraTECH(TM) technology is designed to enhance substances such as pharmaceutical drugs into a more readily bioavailable form that speeds up their time to effective use. Clinical trials have been analyzing its ability to accomplish this transformation without causing changes that adversely interfere with the drugs’ intended use, such as by inadvertently creating new molecular entities NMEs that would require more complex new regulatory approvals (https://ibn.fm/TLcLX).
“Just last month, Lexaria announced that a human clinical study using DehydraTECH technology demonstrated a rapid and sustained drop in blood pressure along with excellent tolerability,” the podcast states. “Initial results show that blood pressure was reduced across both male and female volunteers and was most pronounced in the first 10–50 minutes of the study treatment, reinforcing pre-existing findings demonstrating that DehydraTECH delivers superior performance over generic controls.”
The company’s focus on DehydraTECH is not only to produce a better solution for delivering blood pressure treatments, but also anti-virals that battle SARS-CoV-2/COVID-19, HIV and other illness-causing invaders.
DehydraTECH is also being looked at as a way of making nicotine orally ingestible at a level of quick absorption and efficacy superior to smoked and vaped drugs with the intent of creating a desirable and less harmful alternative to lung-harming inhalation of the substances (https://ibn.fm/COLsW).
Last month Lexaria chose to delist its common shares from the Canadian Securities Exchange in order to focus on trading on the Nasdaq Capital Markets (Nasdaq ticker LEXX), where it has been seeing greater liquidity and can reduce the fees and managerial commitment that went into a dual listing (https://ibn.fm/CaOFZ).
The company’s July 10-Q filing with the Securities and Exchange Commission noted that revenues more than doubled between May 2020 and May 2021, driven by intermediate product sales of DehydraTECH-enabled powders that companies can purchase to include in their products and licensing fees arising from definitive agreements for the DehydraTECH technology (https://ibn.fm/krv09).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.